(Q36750548)

16 August 2017

Tumour budding with and without admixed inflammation: two different sides of the same coin? (English)

1 reference

16 August 2017

Nicole Max

1

1 reference

16 August 2017

Lars Harbaum

2

1 reference

16 August 2017

Marion J Pollheimer

3

1 reference

16 August 2017

Richard A Lindtner

4

1 reference

16 August 2017

Peter Kornprat

5

1 reference

16 August 2017

Cord Langner

6

1 reference

16 August 2017

language of work or name

English

0 references

publication date

14 January 2016

1 reference

British Journal of Cancer

16 August 2017

1 reference

16 August 2017

114

1 reference

16 August 2017

4

1 reference

16 August 2017

368-371

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

16 August 2017

start time

14 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bjc.2015.454

0 references

cites work

Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumor budding in colorectal carcinoma: time to take notice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumour budding: a promising parameter in colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumour budding in colorectal carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

REporting recommendations for tumour MARKer prognostic studies (REMARK)

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumour budding at invasive margins and outcome in colorectal cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumor budding as a prognostic marker in stage-III rectal carcinoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Inflammation and prognosis in colorectal cancer.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815770

Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma

5 September 2018

1 reference

12 December 2020

Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer

1 reference

12 December 2020

The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer

1 reference

12 December 2020

Peritumoral eosinophils predict recurrence in colorectal cancer

1 reference

12 December 2020

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2015.454

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

26766735

1 reference